Pantherna’s innovative technology platform has a focus on developing advanced nanoparticle solutions for the cell-selective delivery and expression of mRNA therapeutics. We are based in Hennigsdorf in the state of Brandenburg with laboratory facilities at the Bayer Pharma Campus in Berlin, Germany.
Pantherna´s mRNA therapies are based on its two fundamental technology pillars, PTXmRNA™ and PTXΔLNP™, enabling robust expression of the desired protein in the correct clinical setting in order to exploit its therapeutic potential.
Our current focus is the development of a systemic mRNA therapy for pulmonary edema by restoring endothelial cell function in the lung via expression of therapeutic proteins for vascular barrier stabilization in a highly spatial manner.
Pantherna Therapeutics is open to all types of collaborations with pharmaceutical and biotech companies.We wish to partner our in-house development programs at the pre-clinical or clinical stage.
Pantherna is supported by public funding from the EU (EFRE). EFRE is provided by the State Brandenburg through the program “ProFIT”:
#80258140/ 41 ProFIT: „Vaskularspezifische Transportsysteme für Nukleinsäure in 16761 Hennigsdorf, Neuendorfstraße 20b“
Mit der Durchführung des AP#3, Thema: Untersuchung der in AP#1 erforschten Testformulierungen auf immunstimulierendes Potenzial anhand diverser Vergleichsmessungen von Lipid-und Polymer-Formulierungen“ (Zeitraum vom 15.4.2021-31.12.2022), wurde die Helmholtz-Zentrum hereon GmbH, [Institut für Aktive Polymere, Hereon Teltow, Abteilung Stammzellmodifikation und Biomaterialien, Haus M, Raum 202, Kantstr. 55, D-14513 Teltow] beauftragt.
Innovationsforum Hennigsdorf
Neuendorfstrasse 20b
D-16761 Hennigsdorf
Phone +49(0)3302-202 240-0
Fax: +49(0)3302-202 240-1